Comparative Pharmacology
Head-to-head clinical analysis: KEPPRA versus MILONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEPPRA versus MILONTIN.
KEPPRA vs MILONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.
None Documented
None Documented
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (CrCl <30 mL/min); clinical context: dosing interval adjustment required in renal disease.
Terminal elimination half-life is 6–8 hours in adults, longer in children (8–12 hours) and elderly (10–14 hours); clinical context: requires multiple daily dosing to maintain therapeutic levels.
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
Primarily hepatic metabolism and renal excretion; approximately 60% of a dose is excreted in urine as conjugated metabolite (phensuximide glucuronide), with 15% as unchanged drug; 20% eliminated in feces.
Category C
Category C
Antiepileptic
Antiepileptic